Contractpharma Biopharma Faces Supply Chain Disruptions Amid Geopolitical Instability
Article Content
- •Biopharma companies are reassessing CDMO resilience due to systemic supply chain risks.
- •Only 22% of pharma firms were evaluating geopolitical risks as of late 2025.
- •Flexible supply models like Just-in-Time are essential for adapting to disruptions.
Biopharmaceutical companies are increasingly assessing the resilience of contract development and manufacturing organizations (CDMOs) due to systemic risks in supply chains. Disruptions from geopolitical instability, adverse weather, and regulatory changes have exposed vulnerabilities in clinical supply chains. Only 22% of global pharma companies were actively evaluating these risks by the end of 2025. The industry is shifting towards flexible supply models, such as Just-in-Time (JIT) approaches, to adapt to changing demands. Current practices often fail to accommodate the dynamic nature of drug development, leading to inefficiencies and potential delays in delivering therapies to patients. Companies are urged to map vulnerabilities in their supply networks and consider geographic concentration and material dependencies when selecting CDMOs. The need for resilience in supply chains is critical as operational bottlenecks can directly impact clinical development timelines and commercial launch readiness.
Ask AI about this cluster
Answers cite the sources they use